ChatBot Beta

Company VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:37:09 2025-02-11 pm EST			5-day change	1st Jan Change
2.380 ^USD	-2.06%		+0.85%	-28.96%

Jan. 06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI
Dec. 23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT

Business description: VYNE Therapeutics Inc.

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Number of employees: 10

Sales by Activity: VYNE Therapeutics Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Development and Commercialization of Foam-Based Formulations	443K	20.99M	14.76M	477K	424K

See all business segments

Managers: VYNE Therapeutics Inc.

Director	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	59	2020-02-29
Tyler Zeronda DFI	Director of Finance/CFO	39	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	52	2020-02-29
Mutya Harsch LAW	General Counsel	51	2020-02-29

See VYNE THERAPEUTICS INC. governance

Members of the board: VYNE Therapeutics Inc.

Manager	Title	Age	Since
David Domzalski BRD	Director/Board Member	59	2020-02-29
Sharon Barbari BRD	Director/Board Member	71	2020-02-29
Steven Basta BRD	Director/Board Member	60	2014-12-31
Anthony Bruno BRD	Director/Board Member	69	2020-02-29
Elisabeth Sandoval BRD	Director/Board Member	63	2019-02-28
Pat LePore BRD	Director/Board Member	70	2020-09-09
Christine Borowski BRD	Director/Board Member	48	2023-12-31

Composition of the Board of Directors

Shareholders: VYNE Therapeutics Inc.

Name	Equities	%	Valuation
Eventide Asset Management LLC 9.452 %	1,394,336	9.452 %	3 M $
Eventide Asset Management LLC 9.452 %	1,394,336	9.452 %	3 M $
Cormorant Asset Management LP 9.452 %	1,394,336	9.452 %	3 M $
Cormorant Asset Management LP 9.452 %	1,394,336	9.452 %	3 M $
Citadel Securities GP LLC 8.049 %	1,187,413	8.049 %	3 M $

List of VYNE THERAPEUTICS INC. shareholders

Company details: VYNE Therapeutics Inc.

VYNE Therapeutics, Inc.

685 Route 202/206 North Suite 301

08807, Bridgewater

http://www.vynetherapeutics.com

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VYNE THERAPEUTICS INC.	-2.06%	+0.85%	+14.98%	-74.11%	35.85M
VERTEX PHARMACEUTICALS INCORPORATED	-2.61%	-5.01%	+9.45%	+95.86%	121B
REGENERON PHARMACEUTICALS, INC.	-3.07%	-4.30%	-29.56%	+4.49%	73.89B
ARGENX SE	-2.21%	-1.90%	+70.92%	+144.24%	39.68B
BIONTECH SE	-1.01%	-2.68%	+21.46%	-33.31%	27.63B
BEIGENE, LTD.	+1.33%	-0.39%	+51.48%	+9.77%	23.44B
WUXI APPTEC CO., LTD.	-1.86%	+3.88%	+8.26%	-33.02%	22.97B
SUMMIT THERAPEUTICS INC.	-5.83%	-5.97%	+315.20%	+814.62%	15.12B
INSMED INCORPORATED	+1.73%	-2.05%	+185.43%	+239.97%	13.98B
NEUROCRINE BIOSCIENCES, INC.	-2.29%	-23.86%	-11.03%	+35.68%	12.03B
Average	-1.78%	-1.08%	+63.66%	+120.42%	34.98B
Weighted average by Cap.	-2.18%	+0.27%	+31.41%	+92.35%